|
Post by dreamboatcruise on Feb 10, 2017 13:34:32 GMT -5
All i think about when i hear all of the restrictions and how MNKD can't say stuff is all the adds i see for drugs that have 9M warnings about the side effects. When i hear it i think, how can people even consider this stuff, yet there it is on TV and i'm sure lots of people are hearing it and enough are buying it. <headscratch> The formula for pharma ads has been fine tuned over the years. They are cleverly constructed to distract attention from the warnings but embed the drug name in one's mind. Short of a certain 4 hour side effect that caught peoples' attention, I think warnings are rarely remembered... but those that believe they might have the ailment remember the drug name. In general people on drug commercials are happy and living wonderful lives... running on the beach, dining at fine restaurants, flying kites with kids, soaking in tubs watching the sunset... send me a bottle of each... I'll take all of it to live that life.
|
|
|
Post by dreamboatcruise on Feb 10, 2017 13:37:26 GMT -5
Can we use the chart that the FDA produced in their Afrezza information package? I couldn't reproduce it here but it shows the pharmacodynamics of Afrezza pretty clearly. See Figure 3 at the FDA paper here: www.accessdata.fda.gov/drugsatfda_docs/label/2014/022472lbl.pdfBoth A and B graphs in figure 3 show the insulin and outsulin features of Afrezza, IMO. Could we add comments pointing out what is clearly shown in the charts? Go to www.afrezza.com/afrezza-mealtime/That is likely what MNKD is allowed to say. Perhaps they have been working with FDA for something more... but that would be pure speculation, and even if they try they may not be successful.
|
|
|
Post by peppy on Feb 10, 2017 18:07:23 GMT -5
Can we use the chart that the FDA produced in their Afrezza information package? I couldn't reproduce it here but it shows the pharmacodynamics of Afrezza pretty clearly. See Figure 3 at the FDA paper here: www.accessdata.fda.gov/drugsatfda_docs/label/2014/022472lbl.pdfBoth A and B graphs in figure 3 show the insulin and outsulin features of Afrezza, IMO. Could we add comments pointing out what is clearly shown in the charts? Go to www.afrezza.com/afrezza-mealtime/That is likely what MNKD is allowed to say. Perhaps they have been working with FDA for something more... but that would be pure speculation, and even if they try they may not be successful. I have looked at this and to my minds eye it is at first confusing. Stated in this order. "Afrezza goes to work quickly, reaching maximum effect in approximately 53 mins." "Afrezza reaches maximum peak levels in 12 to 15 mins."
Insulin and Outsulin; Outsulin is talked about. (In actuality there is no Outsulin.)
|
|
|
Post by johntherancher on Feb 10, 2017 19:23:06 GMT -5
You're correct Peppy. The chart is confusing, I guess because, as the asterisk below the chart says, "* Despite the faster absorption of insulin (PK) from Afrezza, the onset of activity (PD) was comparable to insulin lispro. " Personally, I don't think the chart shows that the onset of the two drugs was comparable. When I look at the chart, especially the B half, I see the faster action of Afrezza and the faster exit of Afrezza than the comparable Lispro. Afrezza, to me anyway, shows the human insulin reaching the patient quicker and exiting the patient quicker than Lispro. My question about how we might use the chart assumed using the chart itself to help explain Afrezza's action and pretty much ignoring the FDA's use. My use of Mankind's "insulin and outsulin" was my attempt to use shorthand. Sorry if it didn't help explain the chart.
|
|
|
Post by peppy on Feb 10, 2017 19:42:38 GMT -5
You're correct Peppy. The chart is confusing, I guess because, as the asterisk below the chart says, "* Despite the faster absorption of insulin (PK) from Afrezza, the onset of activity (PD) was comparable to insulin lispro. " Personally, I don't think the chart shows that the onset of the two drugs was comparable. When I look at the chart, especially the B half, I see the faster action of Afrezza and the faster exit of Afrezza than the comparable Lispro. Afrezza, to me anyway, shows the human insulin reaching the patient quicker and exiting the patient quicker than Lispro. My question about how we might use the chart assumed using the chart itself to help explain Afrezza's action and pretty much ignoring the FDA's use. My use of Mankind's "insulin and outsulin" was my attempt to use shorthand. Sorry if it didn't help explain the chart. good point. quote: " Despite the faster absorption of insulin (PK) from Afrezza, the onset of activity (PD) was comparable to insulin lispro." www.mannkindcorp.com/Collateral/Documents/English-US/Baughman%20poster%20100-LB%20FINAL%20X2.pdf
Quote: Hmmm, Is only the phase two being measured here with onset of activity? www.screencast.com/t/pYQ4TMFaY www.screencast.com/t/qHsWcjqc
It seems times on lispro will vary from person to person and same person from time to time. The asterick. Page 7.
www.accessdata.fda.gov/drugsatfda_docs/label/2013/020563s115lbl.pdf
Well the label change, change the above?
|
|
|
Post by johntherancher on Feb 10, 2017 22:05:15 GMT -5
Someone smarter than me should be compiling the various studies to present a more accurate view of Afrezza advantages. Whether or not we can get a label change, I don't know. I do know that we are in a position where risks should be taken or we will not continue to exist as a drug company. For this reason we should do our best to reach out and connect to the PWD population to convince them to try Afrezza. We're in our last inning, that's my opinion. Take some chances instead of the CYA approach.
|
|
|
Post by peppy on Feb 10, 2017 22:26:54 GMT -5
All the type ones I know/knew are dead.
added * a 30 year old type one I know, is alive. Daughter friend, She is a physician.
|
|
|
Post by mango on Feb 11, 2017 6:42:45 GMT -5
The times that I have mentioned Afrezza to diabetics were all unplanned and stemmed from organic conversation. One particular time that truly was the real-life awe inspiring moment for me was seeing grown adults acting like they were kids on Christmas day.
Just from me merely mentioning there is an inhaled insulin available that is used with an inhaler about "yay" size, was all it took. Of course, they had never heard of such a thing before, and I didn't even have a chance to say another word before these folks were already on their iPhones looking at the Afrezza website, and literally in awe reading about it out loud. I showed them the provider link on the site and recommended them to try contacting those people first to discuss it, etc.
I swear I was literally without words seeing the reactions and excitement. I do not have diabetes, so this was truly the first time in my life where I felt speechless and awestruck about diabetes. It's one thing to read and watch testimonies, but experiencing 'one of those moments' in person is something else.
There truly are people out there waiting for an alternative. It was a small, unforgettable moment for me to see smiling, happy faces like that, and somehow we went from talking about something completely unrelated to health and into diabetes and I did not even know these people were diabetics to begin with. That is why it hit me so hard. I can't really describe any of this in words. It is really that kind of stuff that I love and want to see more of.
Anyways, I guess my point is that MannKind honestly doesn't need anything special at all incorporated into their advertisements for TV. They really only have to present what they have, in a straightforward manner, no graphs or special scenes or "important" people. When something that can dramatically impact someone's life for the better, everything else surrounding the message (Afrezza) falls to deaf ears and blind eyes. One key component to this is the inhaler. When people think of an inhaler they think of an MDI. They get to discover not only a new amazing alternative, but an entirely new kind of inhaler as well.
|
|
|
Post by liane on Feb 11, 2017 6:54:59 GMT -5
mangoHow about a few breaks in your text. This is too hard to read.
|
|
|
Post by sportsrancho on Feb 11, 2017 9:25:09 GMT -5
The times that I have mentioned Afrezza to diabetics were all unplanned and stemmed from organic conversation. One particular time that truly was the real-life awe inspiring moment for me was seeing grown adults acting like they were kids on Christmas day. Just from me merely mentioning there is an inhaled insulin available that is used with an inhaler about "yay" size, was all it took. Of course, they had never heard of such a thing before, and I didn't even have a chance to say another word before these folks were already on their iPhones looking at the Afrezza website, and literally in awe reading about it out loud. I showed them the provider link on the site and recommended them to try contacting those people first to discuss it, etc. I swear I was literally without words seeing the reactions and excitement. I do not have diabetes, so this was truly the first time in my life where I felt speechless and awestruck about diabetes. It's one thing to read and watch testimonies, but experiencing 'one of those moments' in person is something else. There truly are people out there waiting for an alternative. It was a small, unforgettable moment for me to see smiling, happy faces like that, and somehow we went from talking about something completely unrelated to health and into diabetes and I did not even know these people were diabetics to begin with. That is why it hit me so hard. I can't really describe any of this in words. It is really that kind of stuff that I love and want to see more of. Anyways, I guess my point is that MannKind honestly doesn't need anything special at all incorporated into their advertisements for TV. They really only have to present what they have, in a straightforward manner, no graphs or special scenes or "important" people. When something that can dramatically impact someone's life for the better, everything else surrounding the message (Afrezza) falls to deaf ears and blind eyes. One key component to this is the inhaler. When people think of an inhaler they think of an MDI. They get to discover not only a new amazing alternative, but an entirely new kind of inhaler as well. No truer words...thank you for sharing that! The people who are not over extended in their investment, ( that's not me.) Or ones who have thrown their investment away out of frustration. Just can't look at things quite as clearly. IMO Mango is neither of those.. And like he said in another post ... ( The turn around has been happening since last year.)
|
|
|
Post by sayhey24 on Feb 11, 2017 9:30:49 GMT -5
I would go the natural route. afrezza is the only diabetes treatment which uses the exact same insulin which is produced by the pancreas which is why their body will use it like a healthy body. I would think an ad agency could spin a compelling story around that as to why all diabetics at all stages should be using it. Instead of someone dancing through a park like Toujeo they could show some hard facts like CGM pictures from the clap study.
|
|
|
Post by lennymnkd on Feb 11, 2017 9:50:49 GMT -5
As I've mentioned numerous times before , How about giving it a "WHOLE FOODs TYPE IMAGE " with the backing of FDA approval , for the best of legitimacy . Not to mention as a bonus it's inhaled . Needle free ! And synergies with a CGM IS SECOND TO NONE /
|
|
|
Post by agedhippie on Feb 11, 2017 10:41:21 GMT -5
As I've mentioned numerous times before , How about giving it a "WHOLE FOODs TYPE IMAGE " with the backing of FDA approval , for the best of legitimacy . Not to mention as a bonus it's inhaled . Needle free ! And synergies with a CGM IS SECOND TO NONE / Because Type 1 diabetics don't care about whole food images. They know the stuff (including Afrezza) is made in huge steaming vats of mutant E.coli so it's hardly natural. What matters is the benefits - this is the part people seem to consistently miss. As to CGMs - remember that Dexcom has 150,000 users globally, and a lot of those users are not using it.
|
|
|
Post by sportsrancho on Feb 11, 2017 10:53:45 GMT -5
I really like simple, and showing how small the dreamboat is.
|
|
|
Post by sayhey24 on Feb 11, 2017 11:37:17 GMT -5
I really like simple, and showing how small the dreamboat is. Simple is good. I would tweak it and add something like "afrezza provides near normal pancreatic meal time function and is the only treatment using the exact same insulin as the body naturally uses"
|
|